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Introduction
Clinical research is undergoing a major shift. No longer are clinical 
trials primarily conducted in developed countries. In the past 10 
years, the number of clinical research sites outside the United 
States has more than doubled.1 China, with its large population 
and increasing importance as a key player in global health, has 
become an attractive country for conducting clinical trials.2 
Among countries active in research, China boasts the highest 
average relative annual growth rate for research.3 As clinical trials 
are increasingly expanded to developing nations, researchers must 
ensure cultural relevance of subject recruitment and the consent 
process and preservation of Western ethical standards of patient 
autonomy and disclosure of relevant information. Understanding 
patients’ attitudes toward participation in clinical research in 
different countries is critical to the effective and ethical design 
of cross-cultural collaborative studies.4
The majority of studies on patient attitudes toward clinical 
research have been conducted in Western countries. Surveys of US 
and European patients show generally favorable attitudes toward 
clinical trials with patients citing altruism and personal benefit 
as primary reasons for participation.5–12 However, studies show 
that when approached in both hypothetical and real scenarios 
less than half of eligible patients chose to participate; unease 
with randomization, desire for another treatment, concerns 
about treatment risks, lack of awareness about clinical research, 
and physician-related factors have been identified as reasons for 
patients refusing participation.7,8,10,12–15 Importantly, attitudes 
of patients in different countries may vary due to differences 
in health literacy, cultural values, trust in physicians and the 
healthcare system, and access to care.
The limited data available about Chinese patients’ attitudes 
toward clinical research suggest possible mistrust of clinical trials, 
differing motivations for participation, and misgivings regarding 
the consent process.16–18 However, little can be concluded from 
such a small number of studies. In 2012 and 2013, we surveyed 
patients in urban and rural China and the United States to 
compare their attitudes toward clinical research and factors that 
motivate or deter their participation.
Methods
Study design and site selection
Two comparative survey studies of patients in the United States 
and China were conducted between April and November of 2012 
and June and July of 2013. The 2012 study surveyed patients with 
hepatitis C being followed in hepatology clinics at the University 
of Michigan Health System (UMHS) in Ann Arbor, Michigan, 
United States; People’s Hospital, Peking University Health Science 
Center (PUHSC) in Beijing, China; and Guan County Center for 
Disease Control and Prevention in Hebei, China. The investigators 
at UMHS and PUHSC have been collaborating on a study of 
hepatitis C disease progression in the United States and China. The 
original intention was to conduct this survey at the two hepatology 
clinics run by the investigators. The protocol was later revised to 
include a third site in rural China to determine whether responses 
obtained from patients in Beijing are representative of patients 
in China. Hebei was chosen because the PUHSC investigators 
had been following a cohort of patients who acquired hepatitis 
C virus infection through contaminated plasma. Hebei is a rural 
area 35 miles from Beijing and most residents there are farmers 
with limited education.
The 2013 study surveyed patients not under the care of the 
investigators to eliminate biases due to patients’ relations with 
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the investigators and to elicit responses of patients that might 
have less prior exposure to research. Three sites were selected: 
a general medicine clinic at an UMHS off-site multidisciplinary 
clinic 5 miles from the main hospital in Ann Arbor, Michigan, 
United States and two multidisciplinary clinics in Beijing, China: 
one at Zhan Lan Lu Hospital in Beijing city and another one 
at Sha He Hospital in Chang Ping, a rural town 27 miles from 
the Beijing metropolis. Both study sites in Beijing are affiliated 
with PUHSC.
Adults were randomly recruited in-person at the time of their 
clinic visits after informed consent was obtained. In the United 
States, the English survey was self-administered by patients. At all 
sites in China, a researcher administered the survey to patients in 
Chinese due to concerns of low literacy. Data were entered into 
a secure online database accessible by the research team in both 
countries. The research protocols were reviewed and approved 
by the Institutional Review Boards of both the University of 
Michigan and Peking University.
Survey design
Both surveys were initially prepared in English by UMHS 
investigators, reviewed and approved by the PUHSC investigators, 
and then translated into Mandarin Chinese by professional 
translators at PUHSC. Accuracy of the translation was verified 
by two native Chinese speaking investigators at UMHS and minor 
revisions were made. Both surveys were pilot tested in patients 
in the United States and patients in Beijing and revised based on 
feedback from these patients. The 2013 survey included most of 
the questions in the 2012 survey with minor changes based on 
feedback from the 2012 participants.
In both surveys, patients were asked about prior participation 
in research and their greatest concern about participating 
in research. Five-point Likert scales were used for responses 
to statements about the likelihood of participating in clinical 
research based on incentives/disincentives and importance of 
various factors when asked to join a research study. Two sections 
on perceived benefits of research participation and privacy 
concerns were added to the 2013 survey. Both 2012 and 2013 
surveys contained a section on demographics (see supplementary 
material for a copy of the surveys).
Data analyses
Data from all three sites in both surveys were downloaded 
from the electronic database and analysis was performed using 
Statistical Package for the Social Science (SPSS version 20; IBM, 
Armonk, NY, USA). During implementation of the 2013 survey 
at Chinese sites, it was discovered that the revised translation of 
questions regarding the influence of incentives/disincentives on 
decision to participate in a research study based on feedback from 
2012 participants resulted in ambiguity and responses to those 
questions in the 2013 study were not included in this analysis.
Data were presented as median and range or number and 
percent. Categorical variables were compared using chi-squared 
tests and continuous variables using t-tests. Responses from each 
of the three sites in the 2012 survey and in the 2013 survey were 
compared. Univariate and multivariate logistic regression were 
conducted to explore the effects of study site, patient gender, age, 
education, and prior participation in research on concerns over 
personal safety and benefit and importance of being informed of 
risks of participating in research. Note that p values <0.05 were 
considered statistically significant.
To further explore factors associated with responses, patient 
responses to the 2012 survey at all three sites and to the 2013 
survey in the United States between patients with and without 
prior research participation, and patient responses to the 2012 
survey in the United States between white and African Americans 
were compared. The impact of prior research participation on 
responses to the 2013 survey in China was not examined because 
>90% of patients had no prior research participation. The impact 
of race on responses to the 2013 survey in the United States was 
also not examined because information on race was not collected.
Results
The 2012 study surveyed 525 patients (186 US, 186 urban China, 
153 rural China). The 2013 study surveyed a total of 769 patients 
(437 US, 240 urban China, 92 rural China), but 5.7% of US patients, 
14.2% of urban China, and 21.7% of rural China surveys were 
discarded because responses to questions in the demographics 
section were incomplete. Therefore, only 690 patients from the 
2013 study (412 US, 206 urban China, 72 rural China) were 
included in the analyses.
Characteristics of patients analyzed
Characteristics of the patients analyzed are shown in Table 1. 
Roughly half of the patients surveyed in 2012 were men with a 
significantly higher percent of men at the US site (62.9% US vs. 
52.2% urban China and 41.2% rural China). By contrast, more 
than 60% of the patients surveyed in 2013 were women with a 
similar gender distribution across the three sites. The median ages 
of the six cohorts of patients were 51–56 years (range 19–86). In 
both surveys, US patients were significantly more likely to have 
attended at least some college than those in urban China, and 
urban Chinese patients were significantly more likely to have 
attended at least some college compared to those in rural China. 
At all three sites, patients in the 2013 survey were significantly 
more likely to have attended at least some college than those in 
the 2012 survey (p < 0.001). In the 2012 survey, 77.3% of US 
patients were white and 16.8% were African American; >90% 
of Chinese patients were Han Chinese. Race was not captured 
in the 2013 survey.
Previous participation in research
A significantly higher percent of patients in the 2012 survey 
had previously participated in research studies than those in 
the 2013 survey (54.5% vs. 31.9%, p < 0.001; Table 1). In the 
2012 survey, rural Chinese patients were most likely to have 
previously participated in clinical research (80.4% vs. 51.6% US 
[51.7% of white and 48.4% of African American] and 36% urban 
Chinese). In the 2013 survey, the proportion of US patients who 
had previously participated in clinical research was similar to 
that in the 2012 survey (48.9% vs. 51.6%) while the proportion 
of Chinese patients who had previously participated in clinical 
research was markedly lower (8.3% vs. 36% urban and 2.8% vs. 
80.4% rural Chinese) than those in the 2012 survey.
Most important concern about participation in research
When asked the biggest concern about participating in a research 
study, both surveys showed that US patients were far more likely 
to have no concerns (21.6–32.4%) compared to Chinese patients 
(1.6–2.9% urban and 1.4–10.7% rural Chinese, p < 0.001 and 
p < 0.001, respectively for 2012 and 2013; Figure 1). The most 
common concerns of US patients in both surveys were safety, 
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privacy and confidentiality, and time required. Personal safety 
was a top concern for many urban and rural Chinese patients, 
particularly those in the 2013 survey (62.1% urban and 64.8% 
rural Chinese). Chinese patients, particularly rural Chinese in the 
2012 survey (63.3%) were more concerned about the likelihood 
of self-benefit from research participation while few US patients 
(8.1%) were concerned about self-benefit. Few patients at any of 
the three sites in either survey had major 
concerns about the possibility of receiving 
placebo treatment, trust in the study and the 
research team, or cost to them or their health 
insurance. In the United States, patients 
with prior research participation had 
more concerns about safety (22.9% prior 
participation vs. 10.1% no participation, p = 
0.02) in the 2012 survey but not in the 2013 
survey (17.8% prior participation vs. 24.1% 
no participation). Responses to this question 
were similar between Chinese patients with 
and without previous exposure to research.
Importance of information disclosed 
about research
Patients from the United States ranked the 
importance of being informed on all aspects 
of a research study higher than patients in 
China in both 2012 and 2013 surveys, and 
responses of urban and rural Chinese patients 
were similar in both surveys (Figure 2). 
The differences between US and Chinese 
patients’ responses were most pronounced 
regarding being informed of their freedom 
to choose whether to participate in a study 
and to leave a study at any time with Chinese 
patients ranking the importance of those 
options lower than US patients (25.4–
52.9% Chinese patients vs. 80.7–83.3% US 
patients considered them important or very 
important). The vast majority of the patients 
at all three sites in both surveys considered it 
important or very important to be informed 
of the side effects and risks of participating 
in a research study with patients from rural 
China in the 2012 study ranking this lower 
than the other five cohorts. In the 2012 survey, 
Chinese patients without prior research 
participation felt it was more important to be 
informed that they could speak with others 
about the study (61.5–73.3% no participation 
vs. 46.3–52.1% prior participation). Other 
responses in patients with or without prior 
research participation were similar at all three 
sites in the 2012 survey and in the United 
States in the 2013 survey. The 2013 survey 
included an additional question regarding 
the importance of having a committee 
review the research study. Over 95% of the 
US patients compared to 77.1% of urban and 
78.9% of rural Chinese patients ranked this 
as important or very important.
Factors influencing likelihood of participation in research
The 2012 survey showed that roughly 70% of Chinese and US 
patients indicated that their doctor mentioning or recommending 
a research study was likely to influence their participation in 
a research study (Figure 3). Receipt of free medical care and 
financial incentive had greater influence on rural Chinese patients’ 
participation in a research study (>80%) compared to 56.8–79.9% 
Figure 1. Greatest concern about research participation. Patients in 2012 and 2013 were asked to select one 
response only to the question “What is your biggest concern about participating in a research study?”. *These 
survey options were added in 2013.
Figure 2. Perceptions about informed consent process. Patients in 2012 and 2013 were asked to respond using 
Likert scale to questions on “How important to you is it that you are informed of…when asked to join a research 
study?” Patients selected one response per question. aThis survey option was added in 2013.
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in urban Chinese and 54.1–67.8% in US patients. Access to better 
care had a stronger positive influence while need for collection of 
blood samples and genetic information had a stronger negative 
influence on urban and rural Chinese patients’ participation in 
a research study than US patients. Their doctor mentioning or 
recommending the study had greater influence on the decision 
to participate in a research study among urban Chinese patients 
and US patients with prior research participation but not among 
rural Chinese patients (data not shown).
Benefit of participation in research
When asked about the greatest benefit of 
participating in a research study, roughly 25% 
of patients from all three sites in the 2013 
survey chose helping others with a similar 
condition (Figure 4). More than half of the US 
patients while only 29.3% of urban and 19.4% 
of rural Chinese patients chose contributing 
to advances in medicine as the most important 
benefit of participating in a research study. 
Approximately one-third of Chinese patients 
(26.8% urban and 40.3% rural) reported 
that improving one’s own health was the 
most important benefit in contrast to 4.1% 
of US patients. Neither access to treatments 
not widely available, receipt of free medical 
care or financial incentive, improved access 
to specialist care, nor decreased wait time 
in clinics were considered to be important 
benefits of participating in a research study 
for either US or Chinese patients.
Concern about release of information
US patients were generally more concerned 
about confidentiality (Figure 5). In the 2013 
survey, only 13.1% of US patients had no 
concerns about privacy compared to 19.9% 
of urban Chinese and 26.8% of rural 
Chinese. Most patients at all three sites 
(79.8% US, 74.6% urban and 64.8% rural 
Chinese) had concerns about release of their 
personal information. A higher percent of 
US patients was concerned about release 
of their medical records or financial status 
compared to Chinese patients.
Factors associated with responses to the 
survey
Multivariate analyses showed that study 
site was a significant predictor of patients’ 
concerns over personal safety and self-
benefit on research participation (p < 0.001; 
Table 2). Study site (and education in 2012 
survey only) was also a significant predictor 
of patients’ assessment of the importance of 
being informed of side effects and risks of the 
research (p < 0.001). However, while Chinese 
patients had greater concerns about their 
personal safety, they ranked the importance 
of being informed of risks of research 
participation lower than US patients.
Discussion
In this survey study comparing patient attitudes toward 
clinical research in the United States, urban China, and rural 
China, responses of patients at all three sites to many items 
were comparable but there were also some striking differences. 
Overall, the responses of urban and rural Chinese patients were 
more similar to each other than to responses of US patients. 
Responses of patients at each site were similar in the 2012 and 
2013 surveys although the participants were enrolled from the 
Figure 3. Perceptions about research participation. Patients in 2012 were asked to respond using a Likert scale 
to the question “How likely are you to participate in a research study if…?”
Figure 4. Greatest benefit of research participation. Patients in 2013 were asked to select one response only to 
the question “What do you think is the greatest benefit of participating in a research study?”
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investigators’ clinics in 2012 and from clinics with no affiliation 
to the investigators in 2013.
Several factors impacted willingness to participate in research 
studies although 20–30% of US patients and 1–10% of Chinese 
patients had no concerns regarding research participation. The 
higher percent of US patients with no concerns may be related to 
a higher frequency of prior participation in research and greater 
familiarity and trust in research and regulatory oversight.
Safety was the biggest concern of Chinese patients more so 
in the 2013 survey than the 2012 survey (>60% 2013 vs. 23–46% 
2012). This is possibly because fewer Chinese patients in the 
2013 survey had prior exposure to clinical research (3–8% 2013 
vs. 36–80% 2012). Among Chinese patients in the 2012 survey, 
rural Chinese had less concerns about safety than urban Chinese 
possibly because most had been followed by the investigators 
for many years and 80% had previously participated in research. 
Lack of prior participation in research was, however, not an 
independent predictor of safety being ranked as the top concern 
in research participation in both 2012 and 2013 surveys. 
Overall, patients without prior participation in research had 
similar responses to those who had previously participated in 
research. Of note, a higher percent of US patients in the 2012 
survey with prior research experience had major concerns 
about safety although these findings were not replicated in the 
2013 survey.
In our study, Chinese patients were less likely than US 
patients to consider review and approval of research studies 
by ethics committees as important and ranked the importance 
of disclosure of risks lower than US patients. These differences 
may be related to Chinese patients’ unfamiliarity with the role 
of ethics committee oversight, mistrust of the review process, or 
their assumption that physicians would not present risky studies 
to their patients. It is also possible that Chinese patients may be 
influenced by reports of corruption scandals involving physicians 
and pharmaceutical companies in China although we are not 
sure if patients particularly those in rural China were aware of 
these reports.16,19–21 Financial disclosures of relationships between 
the pharmaceutical industry and physicians have come under 
increasing scrutiny in Western countries but these policies are 
more lax in other countries including China. Nevertheless, few 
(<10%) cited trust in the study or the research team as their biggest 
concern about research participation. More efforts are needed to 
elucidate which aspects of research pose a 
safety concern to patients.
Not surprisingly, US patients had 
greater concerns about their privacy than 
Chinese patients. When this question was 
probed more deeply in the 2013 survey, 
most (>60%) patients from all three sites 
worried about release of their personal 
information but Chinese patients worried 
less about release of their medical records or 
financial status. The latter may be related to 
differences in clinical practice with Chinese 
patients hand-carrying their own medical 
records which do not contain any financial 
information to clinic visits while US patients’ 
personal, medical, and financial information 
are stored in electronic records that are more 
easily accessed by others. Furthermore, 
Chinese patient visits are often conducted 
in open clinic rooms whereas US clinic rooms are kept private 
for individual consultations, thus leading to differing expectations 
of privacy and confidentiality.
Some studies have shown that the possibility of receiving 
placebo or being randomized to a less desirable treatment can 
be a barrier to research participation.15,22 We did not find this to 
be the case in any of the six cohorts of patients studied possibly 
because we were asking a hypothetical question and the responses 
might have been different if the patients were invited to participate 
in a randomized controlled trial. Traditionally, Chinese patients 
have a greater aversion to blood draw,23 but we did not observe a 
difference between Chinese and US patients when asked whether 
collection of blood samples or genetic testing would impact their 
likelihood of research participation. It is, however, possible that 
Chinese patients particularly those in rural China do not fully 
understand the implications of genetic testing.
Whether research participation would lead to self-benefit was 
a bigger concern and a stronger motivating factor among Chinese 
than US patients. The importance of self-benefit was particularly 
pronounced among rural Chinese in the 2012 survey (>60%), 
possibly because of their lower socioeconomic status and limited 
access to medical care. This is supported by a higher percent of 
this cohort indicating that free medical care or payment would 
increase their likelihood of research participation. We did not 
specify the amount of financial remuneration in our study nor 
collect information on receipt of payment from those who had 
previously participated in research. A survey of Chinese patients 
from predominantly low socioeconomic backgrounds in Shandong 
province similarly revealed that financial incentives were the main 
reason for clinical research participation.18 These patients may be 
less aware of the risks of clinical research or more inclined to make 
trade-offs for a potential gain and are therefore more vulnerable to 
coercion. In our study, significantly fewer rural Chinese patients felt 
it was important for researchers to inform them of all the possible 
side effects or risks of participating in a research study. Both urban 
and rural Chinese patients would also be more willing to participate 
in research to obtain better care from their physicians compared 
to US patients. In China, patient encounters with physicians in 
clinics are usually limited to a few minutes. Participation in clinical 
research often provides greater access to physicians.
A greater emphasis on self-benefit was also observed among 
Chinese patients in the 2013 survey with 27–40% of Chinese 
Figure 5. Concerns about release of information. Patients in 2013 were asked to select all responses that apply 
to the question “Which of the following information would you be worried about being released?”
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patients but only 4% of US patients ranking improvement of 
their own health condition as the greatest benefit of participating 
in a research study. A similar proportion of US and Chinese 
patients considered helping others with the same condition as 
the greatest benefit while a higher proportion of US patients cited 
contributions to scientific advances in medicine as the greatest 
benefit of participating in research. Our findings are similar to 
other studies showing both altruism and personal benefit as 
reasons for research participation.5–12
Conducting research abroad often leads to the question 
whether consent is voluntary particularly in a culture that 
places less value on individual autonomy.24 While all six cohorts 
of our patients considered it important to be informed of the 
purpose and risks of research studies, Chinese patients were 
less interested in being informed of their freedom to choose 
whether to participate in a study or to leave a study at any time. 
Our findings may be related to Chinese culture being more 
paternalistic with less emphasis on individual autonomy; however, 
China is rapidly evolving. Contrary to common belief, we found 
that physicians mentioning or recommending a study did not 
have a greater influence on research participation for Chinese 
patients than US patients. In fact, the 2012 survey found that the 
influence of physicians in Beijing was less than that in Ann Arbor 
indicating a change in physician–patient relation. We did note 
that among those who had previous research participation, their 
doctors mentioning or recommending the study had a greater 
influence on patient participation for both US and urban Chinese 
patients. Informed consent is still a new concept in China even 
among physicians.25 Our results suggest that more efforts are 
needed to educate Chinese patients of their rights and researchers 
must not use cultural differences to justify conducting research 
in developing countries without adhering to ethical standards 
upheld in Western countries.26
To determine factors associated with responses to the survey, 
we focused on three items deemed central to patient participation 
in clinical research: concerns regarding self-benefit and safety when 
considering participation in a research study and importance of 
being informed of the risks of a research study. Univariate analysis 
showed that study site, patient education, and prior participation 
in clinical research were associated with responses to the items 
selected, while study site was the most important predictor of 
response on multivariate analysis. Our findings indicate that 
while education and prior exposure to research are important, 
factors associated with the patients’ place of residence, such as the 
community they identify with and access to resources (including 
medical care and information and knowledge through media, 
friends, and family) have greater influence on patients’ perceptions 
about clinical research. These findings provide insight regarding 
measures to educate the public about risks and benefits of clinical 
research and strategies to improve recruitment of patients from 
diverse socioeconomic backgrounds.
Studies have shown that racial minorities are underrepresented 
in clinical research compared to white patients; however, they are 
just as willing as whites to participate.27,28 In our 2012 survey, a 
similar proportion (roughly half) of African Americans from the 
United States had previously participated in research as whites. 
More African Americans had concerns about participation in 
research, particularly with safety and trust in the study and 
research staff. Interpretation of these data is limited by the small 
number of African Americans in the study, but these findings 
merit further investigations which may shed light on how to 
improve enrollment of African Americans and other minorities 
into future research studies.
Several limitations of this study must be considered. The US 
surveys were conducted in Ann Arbor, Michigan, a university 
town with a higher-than-average education level and the 
Chinese surveys were conducted in Beijing and communities 
close to Beijing. The rural Chinese sites in the two studies were 
also different. Chang Ping, the 2013 site, is a small town closer 
to Beijing and patients were better educated compared to Hebei, 
the 2012 site. The study cohorts may not be representative 
of US or Chinese patients, although we found a striking 
similarity between the results of the 2012 and 2013 surveys, 
which enrolled patients from different clinics with and without 
relations to the investigators. Administration of the survey also 
differed between US and Chinese sites. Trained researchers 
administered the survey to patients at the four Chinese sites 
due to concerns of low literacy while patients completed the 
survey independently at the two US sites. While the original 
intention was to replicate the 2012 survey with two additional 
sections in the 2013 survey, ambiguity due to rewording one 
section of the Chinese version of the 2013 survey forced us to 
abandon analysis of that section; thus, responses to some items 
were not available for comparison.
Conclusions
In this study involving more than 1,200 patients in the United 
States and China, we found that Chinese patients had greater 
concerns about safety while US patients had more concerns 
about privacy regarding participation in clinical research. 
Self-benefit was a more important motivator for participation 
among Chinese patients while altruism and advancing science 
were more important motivators among US patients. While 
Chinese patients had greater concerns about safety, they 
ranked the importance of being informed of risks, freedom 
to leave the study, and ethics committee review and approval 
of research study lower. These findings highlight the need to 
educate Chinese patients about their rights. Financial incentive 
was a greater motivator for participation in clinical research 
among patients from lower socioeconomic areas. This is 
likely true not only in China but also in the United States and 
should serve as a reminder that these patients are vulnerable 
and may become targets of coercion. In summary, our study 
provided important insights into attitudes of Chinese patients 
toward clinical research that would help in the design of cross-
cultural clinical research studies to maximize enrollment while 
upholding Western ethical standards.
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